Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer
Mark M. Awad(Memorial Sloan Kettering Cancer Center), Andrew J. Aguirre(Broad Institute), Julien Dilly(Massachusetts Institute of Technology), Joseph O. Jacobson(Dana-Farber Cancer Institute), Peter Olson(RIKEN BioResource Research Center), Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Kavita Garg, Pasi A. Jänne(Harvard University), Melissa L. Johnson(Tennessee Oncology), Nicole S. Persky(Broad Institute), Piro Lito(Memorial Sloan Kettering Cancer Center), Shengwu Liu(Broad Institute), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Lee P. Lim, Rebecca S. Heist(Massachusetts General Hospital), Xiaoping Yang(Broad Institute), Laura Waters(Mirati Therapeutics (United States)), James G. Christensen, Viola W. Zhu(University of California, Irvine), Lars D. Engstrom(Mirati Therapeutics (United States)), David E. Root(Broad Institute), Lynette M. Sholl(Brigham and Women's Hospital), J. David Lawson(Mirati Therapeutics (United States)), Tejas Patil(Sidney Kimmel Comprehensive Cancer Center), Sai-Hong Ou(University of California, Irvine), Mark Li(University of Iowa)
Cited by 12
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k